Lung Cancer

FDA Grants Priority Review to Osimertinib for Adjuvant Treatment of Early-Stage EGFRm NSCLC
October 20, 2020

The FDA accepted and granted priority review to the supplemental new drug application for osimertinib (Tagrisso) for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer after complete tumor resection with curative intent.

Two Studies Examining Pembrolizumab Combinations Induce Positive Outcomes in Advanced NSCLC
October 19, 2020

Merck announced positive data regarding 2 studies, one examining pembrolizumab in combination with chemotherapy and another in combination with quavonlimab in combination to treat advanced non-small cell lung cancer.

Study Finds Single Dose-Per-Cycle Plinabulin Has Effective Neutropenia Protection Benefit for NSCLC
October 07, 2020

This study found that single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim among adult patients with non-small cell lung cancer.